| Literature DB >> 34070936 |
Efaq Noman1,2, Muhanna Mohammed Al-Shaibani3, Muhammed Adnan Bakhrebah4, Reyad Almoheer5, Mohammed Al-Sahari3, Adel Al-Gheethi3, Radin Maya Saphira Radin Mohamed3, Yaaser Qaeed Almulaiky6,7, Wesam Hussain Abdulaal8.
Abstract
The promising feature of the fungi from the marine environment as a source for anticancer agents belongs to the fungal ability to produce several compounds and enzymes which contribute effectively against the cancer cells growth. L-asparaginase acts by degrading the asparagine which is the main substance of cancer cells. Moreover, the compounds produced during the secondary metabolic process acts by changing the cell morphology and DNA fragmentation leading to apoptosis of the cancer cells. The current review has analyed the available information on the anticancer activity of the fungi based on the data extracted from the Scopus database. The systematic and bibliometric analysis revealed many of the properties available for the fungi to be the best candidate as a source of anticancer drugs. Doxorubicin, actinomycin, and flavonoids are among the primary chemical drug used for cancer treatment. In comparison, the most anticancer compounds producing fungi are Aspergillus niger, A. fumigatus A. oryzae, A. flavus, A. versicolor, A. terreus, Penicillium citrinum, P. chrysogenum, and P. polonicum and have been used for investigating the anticancer activity against the uterine cervix, pancreatic cancer, ovary, breast, colon, and colorectal cancer.Entities:
Keywords: L-asparaginase; anticancer; fungi; marine; production
Year: 2021 PMID: 34070936 PMCID: PMC8229146 DOI: 10.3390/jof7060436
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X
Figure 1Applications of fungi in the environment to medicine.
Figure 2SLR Flowchart adopted with modification from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
(a) Systematic Literature Review (SLR) objectives and questions. (b) Research plan of the SLR.
| (a) | ||
|---|---|---|
| No. | Objectives | Questions |
| 1 | To identify the potential application | How do secondary metabolic substances affect cancer cells? |
| 2 | To verify the effectiveness of | How does the asparaginase work to inhibit the cancer cells? |
|
| ||
|
|
| |
| Context | This SLR presents the potential of secondary metabolic substances as anti-cancer. | |
| Objectives | The objective of the systematic review is to answer the questions regarding the application of secondary metabolic substances for cancer treatment. | |
| Method | The method used in this SLR process is data collection, screening, data verification, data analysis, and discussion. | |
| Result | The result shows the performance of each advanced technology, the advantages, and disadvantages of each method. | |
| Conclusion | The discussion regarding the objectives and questions is successfully achieved with clear discussion. | |
The included and excluded relevant papers per publication year.
| Year | Initial | R | Included | Excluded |
|---|---|---|---|---|
| 2020 | 22 | 0.0182 | 4 | 18 |
| 2019 | 36 | 0.0111 | 5 | 31 |
| 2018 | 29 | 0.0207 | 3 | 26 |
| 2017 | 28 | 0.0143 | 4 | 24 |
| 2016 | 22 | 0.0364 | 5 | 17 |
| 2015 | 24 | 0.0167 | 3 | 21 |
| 2014 | 27 | 0.0222 | 7 | 20 |
| 2013 | 17 | 0.0471 | 6 | 11 |
| 2012 | 20 | 0.0500 | 4 | 16 |
| 2011 | 13 | 0.0462 | 3 | 10 |
| 2010 | 16 | 0.0625 | 6 | 10 |
| Total | 254 | 0.3452 | 50 | 204 |
Figure 3(a). Bibliometric analysis of the publication on the anticancer activity of fungi based on the journals. (b) Bibliometric analysis of the publication on the anticancer activity of fungi based on the countries. (c) Bibliometric analysis of the keywords of the anticancer activity of fungi papers.
Most common enzymes associated with cancer in humans.
| Enzyme | Molecular Structure | Gene Location (Human) | Role | References |
|---|---|---|---|---|
| Sterol O-acyltransferase (ACAT1) |
|
| The enzyme is involved in a variety of cancer types because of its association with increasing cholesteryl ester levels. The anti-cancer drug acts by inhibiting the enzyme leading to suppression of proliferation in a range of cancer cell types. | [ |
| Glutaminase |
|
| The enzyme acts by inhibiting the target breast cancer cells by blocking the conversion of glutamine to glutamate. Therefore, some studies indicated that the enzyme is thereby potentially interfering with anaplerosis and the synthesis of amino acids and glutathione. | [ |
| β-Glucosidase |
|
| β-Glucosidase plays an essential role in the inhibition of cancer cells by combing with cancer-cell-surface antigens leading to converting amarogentin to an active drug that acts on cancer cells and the surrounding antibodies to achieve a killing effect. | [ |
| Lactate dehydrogenase B (LDHB) |
|
| The enzyme is an intracellular enzyme and is released into the bloodstream when the cells are damaged due to tissue destruction caused by tumor growth. Therefore, the increase of enzyme levels in the blood is usually used as indicators of tissue damage. | [ |
| Laccase |
|
| Laccases from basidiomycetes fungi exhibited high potential as anti-cancer as well as having anti-proliferative activities primarily against breast cancer and liver carcinoma cell lines. | [ |
| β-Glucuronidase |
|
| Beta-glucuronidase (βG) is a biomarker for the diagnosis of cancer and prodrug therapy. Therefore, the image βG activity in patients is associated with the personalized glucuronide prodrug cancer therapy. | [ |
| α-amylase |
|
| The experiments conducted on the primary cell cultures of human breast cancer cells exhibited an anti-proliferative effect for salivary α-amylase. | [ |
| Matrix metallopeptidase 9 |
|
| The modulation of gelatinase expression in the host cells is associated with the interactions between cancer cells and host tissues. Therefore, the inhibition of gelatinases by synthetic MMP inhibitors is an attractive approach to block cancer progression. | [ |
Some common drugs used for cancer treatment and their side effects.
| Drug | Formula | Utilization | Side Effects | References |
|---|---|---|---|---|
| Doxorubicin | C17H30ClNO11 | The drug is used as anti-cancer for a wide range of cancers such as hematological malignancies, soft tissue sarcomas, and acute lymphoblastic leukemia | Vomiting, nausea, loss of appetite, diarrhea, darkening of skin or nails, missed menstrual periods, tiredness, weakness, puffy eyelids, eye redness, as well as the appearance of a reddish color to urine, tears, and sweat. | [ |
| Actinomycin d | C62H86N12O16 | The drug has anti-cancer properties against Wilms tumor, Ewing′s sarcoma, rhabdomyosarcoma, testicular cancer, trophoblastic neoplasia, and ovarian cancer. | The drug is associated with low red and white blood cell levels, decrease in the low platelet levels leading to increased risk of infection, anemia, and bleeding. Nausea and vomiting, hair loss, sores in the mouth, skin reactions, diarrhea, acne, peeling, skin eruptions, and sensitivity to sunlight. | [ |
| Flavonoids | The flavonoids have high potential as anti-cancer agents and exhibited great potential against cancer cells. | The side effects have been reported for the flavonoids. However, some reports indicate the presence of anemia, fever, and hives which have been disappeared when treatment was discontinued. | [ | |
| Rapamycin | C51H79NO13 | The drug acts by inhibiting the tumor growth leading to halting tumor cell proliferation, and tumor cell apoptosis, and then suppressing tumor angiogenesis. | The side effects of the drug include stomatitis and mycositis which are associated with high doses or long term used. Moreover, some studies reported non-infectious interstitial pneumonitis and hyperglycemia. | [ |
| Clindamycin | C18H33ClN2O5S | Clidamycin which is classified as a member of the enediyne anti-cancer antibiotic family exhibited cytotoxicities against cancers in vitro and in vivo. | Nausea, diarrhea, and vomiting, heartburn, metallic taste in the mouth, abdominal and joint pain, skin rash, redness, itching, vaginal itching, and burning. | [ |
| Hyaluronic acid | (C14H21NO11)n | The drug is common because it is biocompatible, non-toxic, biodegradable, and non-immunogenic, as well as HA receptors are overexpressed on many tumor cells | Pain, redness, bruising, swelling, and itching. | [ |
| Mitomycin | C15H18N4O5 | Mitomycin is anti-cancer produced | Anorexia, fever, vomiting, and nausea, as well as a blurring of vision, headache, drowsiness, confusion, fatigue, syncope, thrombophlebitis, anemia, diarrhea, hematemesis, and pain | [ |
| Cisplatin | [Pt(NH3)2Cl2] | The drug is among the most effective anti-cancer against solid tumors and acts by damaging DNA and inhibiting DNA synthesis. | Nausea, low blood counts, vomiting, ototoxicity hearing loss, ringing in the ears, kidney toxicity, blood test abnormalities | [ |
| Bleomycin | C55H84N17O21S3 | The drug is used in combination with surgery or radiotherapy against squamous cell cancers, sarcoma, melanoma, both Hodgkin′s and non-Hodgkin′s lymphoma as well as testicular cancer | Fever, chills, redness, stretch marks, and darkening of the skin, peeling and thickening, nail thickening and banding as well as hair loss. | [ |
| Doxorubicin | C17H30ClNO11 | The drug is used as anti-cancer for a wide range of cancers such as hematological malignancies, soft tissue sarcomas, and acute lymphoblastic leukemia | Vomiting, nausea, loss of appetite, diarrhea, darkening of skin or nails, missed menstrual periods, tiredness, weakness, puffy eyelids, eye redness, as well as the appearance of a reddish color to urine, tears, and sweat | [ |
| Actinomycin d | C62H86N12O16 | The drug has anti-cancer properties against Wilms tumor, Ewing′s sarcoma, rhabdomyosarcoma, testicular cancer, trophoblastic neoplasia, and ovarian cancer. | The drug is associated with low red and white blood cell levels, decrease in the low platelet levels leading to increased risk of infection, anemia, and bleeding. Nausea and vomiting, hair loss, sores in the mouth, skin reactions, diarrhea, acne, peeling, skin eruptions, and sensitivity to sunlight | [ |
| Flavonoids | The flavonoids have high potential as anti-cancer agents and exhibited great potential against cancer cells. | Side effects reported for the flavonoids indicate the presence of anaemia, fever, and hives which have been disappeared when treatment was discontinued | [ | |
| Rapamycin | C51H79NO13 | The drug acts by inhibiting the tumor growth leading to halting tumor cell proliferation, and tumor cell apoptosis, and then suppressing tumor angiogenesis. | The side effect of the drug includes stomatitis and mycositis which is associated with high doses or chronically used. Moreover, some studies reported non-Infectious interstitial pneumonitis and hyperglycemia | [ |
| Clindamycin | C18H33ClN2O5S | Clidamycin which is classified as a member of the enediyne anti-cancer antibiotic family exhibited cytotoxicities against cancers in vitro and in vivo. | Nausea, diarrhea, and vomiting, heartburn, metallic taste in the mouth, abdominal and joint pain, skin rash, redness, itching, vaginal itching and burning. | [ |
| Hyaluronic acid | (C14H21NO11)n | The drug is common because it is biocompatible, non-toxic, biodegradable, and non-immunogenic, as well as the HA receptors are overexpressed on many tumour cells | Pain, redness, bruising, swelling, and itching | [ |
| Mitomycin | C15H18N4O5 | Mitomycin is anti-cancer produced by Streptomyces caespitosus and exhibited high efficiency against a wide variety of cancer types | Anorexia, fever, vomiting, and nausea, as well as a blurring of vision, headache, drowsiness, confusion, fatigue, syncope, thrombophlebitis, anemia, diarrhea, hematemesis, and pain | [ |
| Cisplatin | [Pt(NH3)2Cl2] | The drug is among the most effective anti-cancer against solid tumours and acts by damaging DNA and inhibiting DNA synthesis. | Nausea, low blood counts, vomiting, ototoxicity hearing loss, ringing in the ears, kidney toxicity, blood test abnormalities | [ |
Figure 4Chemical structure of drugs used for cancer treatment.
Review of the studies conducted on the application of secondary metabolic products from fungi as anti-cancer agents.
| Fungal Genus | Fungal Species | Active Substances | Effectiveness against Cancer | References |
|---|---|---|---|---|
|
| Alterporriol L (7) | Alterporriol L changed the cancer cell morphology and exhibited a significant inhibition of cell growth, as well as inducing cancer cell apoptosis or necrosis in breast cancer cells lines. | [ | |
| Perylenequinone derivatives | These compounds exhibited cytotoxic activities against human erythroleukemia, human gastric carcinoma cells, and hepatocellular carcinoma cells. | [ | ||
|
| Gliotoxin (10) | Anti-cancer activity and apoptosis of cancer cells and DNA fragmentation, as well as induced activation of caspase-3, 8 and 9, down-regulation of Bcl-2, up-regulation of Bax in human cervical cancer (Hela) and human chondrosarcoma cells. | [ | |
| A. | Preussin (11) (10 µM) | Preussin exhibited an ability to cause cell death as confirmed by caspase-3 immunostaining of breast cancer cells. | [ | |
| Aspergilsmins | The compounds have exhibited anti-cancer activity against human hepatocellular carcinoma cells and prostate cancer cells. | [ | ||
| Hexadecanoic, | The compounds had significantly high cytotoxic activity against colorectal cancer cells. | [ | ||
| The extract exhibited anti-cancer activity against the Hep 2 cell line. | [ | |||
| Butenolide derivatives, Asperlides A–C | The compounds exhibited anti-cancer activity against hepatocellular carcinoma, hepatocellular carcinoma, and pancreatic duct cancer. | [ | ||
|
| Crude ethyl acetate extracts | The extract exhibited anti-cancer activity against HepG2, HCT116, and A375. | [ | |
|
| Physcion (11.8 mg) | The compound induces cell apoptosis through down-regulating of Bcl-2 expression, up-regulating of Bax expression, as well as induced the formation of reactive oxygen species in HeLa cells. | [ | |
| Physcion physcion activated caspase-3,8, 9, Ras, Bcl-xL, and Bcl-2 Bax (0–50 µM) | Physcion decreases cell proliferation and induces cell apoptosis in human prostate cancer cells. | [ | ||
|
|
| 1,4-diacetyl-2,5-dibenzylpiperazine (16), Derivative, A quinazolinone-containing indole derivative, A new ester of 2,4-dihydroxy-6-methylbenzoic acid. | The compounds exhibited anti-cancer activity against human glioblastoma and non-small cell lung cancer Apoptosis-resistant cells, and distinct cancer cell lines. | [ |
| 2,4-dihydroxy-3-methylacetophenone (1), Nortryptoquivaline (2) Chevalone C (3), tryptoquivaline H (4), | Effects on DNA damage, ultrastructural modifications, and intracellular accumulation in lung cancer cells. NS extract has cytotoxicity by inhibiting cell proliferation, increasing intracellular accumulation of Dox, and inducing cell death in lung cancer | [ | ||
|
| Hyalodendrin (251.53 mg) | The compound induces the changes in the phosphorylation status of p53 and altered expression of epithelial cancer cell line | [ | |
|
| 2-Bromogentisyl alcohol (6), 3-hydroxy, benzenemethanol, Epoxydon 6-dehydroxy-6-bromogabosine C, 2-chlorogentisyl alcohol, gentisyl alcohol Griseofulvin (IC50 values of 8.4, 9.7, and 5.7 μM) | The compounds exhibited anti-cancer activity against the human caucasian colon adenocarcinoma cells line | [ | |
| (Z)-Octadec-9-enamide (oleamide) IC50 = 22.79 μg/mL | Anti-cancer activity against breast cancer cells. | [ | ||
| Penicitrinine A (12–100 µM) | The compound induces A-375 cell apoptosis by decreasing the expression of Bcl-2 and increasing the expression of Bax in multiple tumor types | [ | ||
| Anthraquinone Cinnamic acid. (20–100 µg/mL) | The extract enhanced the membrane damage and apoptosis in breast cancer cells. The extract inhibited anti-cancer activity against human breast cancer and HeLa cells. | [ | ||
|
|
| Crude extracts | The extracts exhibited inhibitory potential anti-cancer against A-549 lung carcinoma cells, breast cancer, and human keratinocytes. | [ |
|
| Epoxyphomalin A and B (IC50, 0.17–0.33 μg/mL] | The compound | [ | |
|
| Pentacyclic decalinoylspirotetramic acid, Pyrenosetin D (IC50 values of 77.5 and 39.3 µM) | Pyrenosetin D showed anti-cancer activity against the melanoma cell line and noncancerous keratinocyte cell line. | [ | |
|
| Gusation A, 2-amino-1,3,4-trihydroxy-8-octadecene (18), Vitamin E, Tetradecanoic acid, 12-dimethyl-methyl ester, 2- | The compounds exhibited anti-cancer activity against the HEp2 carcinoma cell line. | [ | |
|
| Cyclosporin A (19), Efrapeptin D (17), Pyridoxatin, Terricolin A, Malettinins B and E, Tolypocladenols (different IC50) | Anti-tumor effects against cancer cell line panel. | [ |
Figure 5Chemical structure of some compounds from fungi with anti-cancer activity.
Figure 6The most common fungal strains with high production of L-asparaginase.
Experimental conditions for producing L-asparaginase from different fungal species.
| Fungal Genus | Fungal Species | Production/Medium/ and Substrate | Factors Investigated | Characteristics | References |
|---|---|---|---|---|---|
|
| MCD | Tween 80 and Triton X-100, | Stable at pH 4–10, at 20–400 °C. | [ | |
| SSF (Tray bioreactor) Cottonseed cake, wheat bran, and red gram husk consecutive | pH-8, 2%( | Maximum activity was 20.58 U/gds after 120 h | [ | ||
|
| SmF and SSF, | Temperature (25–45 °C), time (96–192 h), agitation (0–250 rpm) and inoculum (1–5 mL/100 mL media), l-asparagine and dextrose, | The highest activity (84.3 U) with flaxseed oil cake as the substrate for the production of a purified enzyme with 6.39- fold purity. | [ | |
|
| MCD | pH 6.2, 120 rpm, 32 °C, 72 h | The activity was 47.29 U/ mL. | [ | |
| SSF | Temperature (25–35 °C), initial moisture content (40–60%) and inoculum concentration | The highest activity recorded with passion fruit peel flour (2380.11 U/gds) after 48 h at 30 °C, 3746.78 U/gds with 60% of moisture and (2.1 × 106) spores/g after 24 h at 25 °C. | [ | ||
|
| SmF | Incubation periods (1, 2, 3, 4, | The highest activity (11.01 u/mL) at 30 °C for 7days of incubation pH 7.0, | [ | |
| MCD | 30 °C and incubation periods | Maximum production achieved at 96 h (4 days) with the incorporation of glucose as a carbon source in the culture medium | [ | ||
|
| Fermentation | 30 °C, 120 rpm, 96 h, glucose, sucrose, lactose or fructose, arginine, glutamine, asparagine, tyrosine, leucine, tryptophan, or histidine), urea, ammonium nitrate, sulfate. | Maximum production is of 108 U with glucose, proline, and asparagine. | [ | |
|
| SmF | Dextrose, ammonium sulfate | Activity was recorded 9.18 ± 0.9 U/mL, at 3 g/L Dextrose, 20 g/L ammonium sulphate and 13.69 ± 0.4 U/mL at 2.5 g/L wheat bran after 5 d. | [ | |
| stationary liquid state bioprocesses | Glycerol; L-asparagine; 105 mL−1 of inoculum, incubated for 72 h at 30 °C. | The enzyme activity was 8.3 U min/ mL from | [ | ||
|
| the fermentation process in potato dextrose broth | Temperature (25–35 °C), the incubation period (48–96 h), and initial pH (5–9), L-proline, L-asparagine, ammonium sulfate, yeast extract, sucrose, and glucose. | Maximum activity (2.33 IU/mL) detected at 2.8% L-asparagine 4.0% L-proline, 0.75% Potato dextrose broth, and 0.1% Sucrose. | [ | |
| SSF | pH level (pH), residence time (RT), the time between cycles (TC), and concentration of glucose and L-asparagine. | L-asparaginase activity was 13.7 U/gds was achieved at a residence time of 33.5 min, pH of 5.1, and concentrations of L-asparagine and glucose of 1.2 and 3.0 g/L. | [ | ||
|
|
| MCD | Agitation rate (100–150 rpm), pH (4.0–9.5), temperature (15–40 °C), and (7–29 days), glucose (2–15), starch (2.5–15), yeast extract (2.5–15), | The enzyme activity of 108.95 U/mL was recorded at 120 rpm after at 120 h with L-asparagine, and starch as the carbon source than glucose. | [ |
|
| NA | Temperature, pH, L-Asparagine concentration and glucose concentration. | Optimum enzyme activity of 20.57 U mL−1 was obtained at 30 °C and pH of 7.0 after 60 h | [ | |
|
| SSF | pH value (3.0–8.0), 50 to 86% | Maximal production 113.43 ± 5.11 U/g-ds with 75% of moisture content of 75%, 1 × 108 spores/mL, pH 5.0, at 28 °C for 4 days. | [ | |
|
|
| MCD | pH 6.8, the incubation period was 2–3 days, carbon sources were D-glucose, starch and molasses, glycerol, ammonium sulphate as a mineral nitrogen source, and soybean powder and yeast extract | 1.84-fold increase in enzyme production,
| [ |
SSF, (solid-state fermentation); SmF, (submerged fermentation); NA, (nutrient agar); MCD, Modified Czapek Dox.
Examples for the applications of L-Asparaginase as an anti-cancer.
| Cancer Type | Preparation | Activity | References |
|---|---|---|---|
| Prostate cancer cell lines | L-Asparaginase was incorporated into nano biocomposites synthesized using β-cyclodextrin | The mixture exhibited high activity at the concentration of 125 μg/mL and against lymphoma cancer cells (U937) with IC50 value at 500 μg/mL of β-cyclodextrin-Asparaginase nanobiocomposite. | [ |
| Cervical and brain cancer cell lines | The enzyme was immobilized onto a nanobiocomposite consisting of β-cyclodextrin and Gelatin. | The anticancer activity was 42.13% at 500 μg/mL and 48.60% at 62.5 μg/mL respectively. | [ |
| K562 and HL60 | A crude enzyme was mixed with cell viability and then incubated for 24 h at 37 °C inside a CO2 incubator, thereafter, ten μL of 10% MTT | The toxicity of L-asparaginase against K562 and HL60 cancer cell lines and L6 as normal cells was determined with IC50 values were calculated as 0.4 and 0.5 IU/mL for K562 and HL60 respectively | [ |
| Childhood leukemia | L-Asparaginase with a dose of ≥ 6000 IU/sq m three times weekly. | L-Asparaginase was effective in re-inducing remissions at 9.5% for 300 IU/sq m; 35.1% for 3000 IU/sq m; 53.5% for 6000 IU/sq m; and 62.5% for 12,000 IU/sq m. | [ |
| Acute lymphoblastic leukemia | L-Asparaginase in doses from 10 to 1000 international units/kg body weight per day for 2 to 20 days. | 66% response rate for acute lymphoblastic leukemia and an approximately 12% response rate for nonlymphocytic leukemia. | [ |